SCHEMBL279750

SCHEMBL279750

CCN(CC(=O)c1ccc(C)s1)Cc1ccncc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.43
POLB P06746 3/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 5/20 0.38
MAPT P10636 4/20 0.38
KMT2A Q03164 4/20 0.38
TDP1 Q9NUW8 3/20 0.38
KDM4E B2RXH2 2/20 0.38
GAA P10253 1/20 0.38
DAO P14920 1/20 0.38
PKM P14618 2/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 2/20 0.36
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RECQL P46063 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279743 0.84 NPC1 (0.41) USP2POLBNPC1RAB9AALDH1A1
SCHEMBL280054 0.78 RAB9A (0.41) USP2POLBNPC1RAB9AALDH1A1
SCHEMBL280366 0.76 RAB9A (0.44) POLBNPC1RAB9AALDH1A1KMT2A
SCHEMBL279931 0.75 RAB9A (0.43) POLBNPC1RAB9AALDH1A1KMT2A
SCHEMBL279651 0.74 USP2 (0.43) USP2POLBNPC1RAB9AALDH1A1
SCHEMBL6847657 0.74 ACKR3 (0.48) USP2NPC1RAB9AMAPTKMT2A
SCHEMBL279889 0.74 USP2 (0.43) USP2POLBNPC1RAB9AALDH1A1
SCHEMBL280130 0.72 NPC1 (0.44) POLBNPC1RAB9AALDH1A1MAPT
SCHEMBL280197 0.71 RAB9A (0.48) POLBNPC1RAB9AALDH1A1KMT2A
SCHEMBL279929 0.71 POLB (0.47) POLBNPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL USP2 3755/4885POLB 4352/4885NPC1 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.